Top Markets
Coin of the day
Gamida Cell Ltd. Gamida Cell Ltd.

Gamida Cell Ltd.

GMDA
Pozycja w akcjach #35164
Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated... Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated to pioneering cell therapies aimed at eradicating blood cancers and other severe hematological conditions. The company's leading investigational product, omidubicel—a specialized cell therapy—has successfully concluded its Phase III clinical evaluation for individuals afflicted with high-risk hematologic malignancies. Furthermore, it is currently undergoing Phase I/II trials for patients suffering from severe aplastic anemia. Another significant therapeutic candidate, GDA-201, an immunotherapy harnessing natural killer cells, is progressing through Phase I/II studies to address relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Beyond these, Gamida Cell is actively advancing a broader natural killer (NK) cell pipeline, which includes GDA-301, GDA-401, GDA-501, and GDA-601, with the ambition of treating both hematologic cancers and solid tumors. Founded in 1998, the company maintains its corporate headquarters in Jerusalem, Israel.
Cena akcji
$0.0327
Ostatnia synchronizacja: 2025-06-17
Kapitalizacja rynkowa
$4.34M
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
IL
Handel Gamida Cell Ltd. (GMDA)

Kategoria

Historia ceny akcji dla Gamida Cell Ltd. (GMDA)
Najwyższa cena zamknięcia: $0.03 dnia 2025-06-01

Najniższa cena zamknięcia: $9.40 dnia 2018-10-01
Historia cen akcji firmy Gamida Cell Ltd. od 2018 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2025 117.76%
2024 -95.28%
2023 -75.22%
2022 -48.32%
2021 -71.87%
2020 84.95%
2019 -55.53%
2018 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$505.24 28.63%
US
$846.09 29.41%
NL
$731.69 6.47%
CH
$1.07K -6.40%
KR
$251.82 11.75%
BE